• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.


Epigeneics include any process that alters gene activity without changing the DNA sequence, and leads to modifications that can be transmitted to daughter cells. Many types of epigenetic processes have been identified—they include DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs.

Many different DNA and histone modifications have been identified to determine the epigenetic landscape. DNA methylation is mainly mediated by DNA-methyl transferase (DNMT), there are two known types of DNMT, namely DNMT1, which preserves preexisting pattern of methylation after cell replication, and DNMT3A/B, so-called “de novo” DNMT, which methylate previously unmethylated DNA. Histone modifications mainly include acetylation, methylation, phosphorylation, and ubiquitination. The acetylation of histones can be mediated by histone acetyltransferases (HATs) and histone deacetyltransferases (HDACs), while Histhone demethylation is performed by two classes of histone demethylases: lysine-specific demethylase (LSD) family proteins (LSD1 and LSD2) and JmjC domaincontaining histone demethylase (JHDM). Furthermore, enzymes involved in epigenetic modifications can also be governed by miRNAs. For example, miR-34a can directly inhibit the activities of SIRT1 to regulate cholesterol homeostasis.

The accumulated evidence indicates that many genes, diseases, and environmental substances are part of the epigenetics picture. At the FDA, scientists are investigating many drugs that function through epigenetic mechanisms. Drugs that inhibit DNA methylation or histone deacetylation have been studied for the reactivation of tumor suppressor genes and repression of cancer cell growth. Epigenetic inhibitors can also work alone or in combination with other therapeutic agents.



[1] Bob Weinhold. Environ Health Perspect. 2006 Mar; 114(3): A160–A167.

[2] Xu W, et al. Genet Epigenet. 2016 Sep 25;8:43-51.

[3] Biswas S, et al. Pharmacol Ther. 2017. doi: 10.1016/j.pharmthera.2017.02.011.

[4] Perri F, et al. Crit Rev Oncol Hematol. 2017 Mar;111:166-172.

Products of the following targets

Products of the following indications

Tags: buy Epigenetics materials | Epigenetics ic50 | Epigenetics price | Epigenetics cost | Epigenetics inhibitor dmso | Epigenetics purchase | Epigenetics inhibitors manufacturer | Epigenetics research buy | Epigenetics order | Epigenetics mouse | Epigenetics chemical structure | Epigenetics pharmaceuticals | Epigenetics weight | Epigenetics active molecules | Epigenetics APIs supplier | Epigenetics in vitro | Epigenetics cell line | Epigenetics concentration | Epigenetics signaling pathway